%0 Journal Article
%T Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development.
%A Xiang D
%A He A
%A Zhou R
%A Wang Y
%A Xiao X
%A Gong T
%A Kang W
%A Lin X
%A Wang X
%A  
%A Liu L
%A Chen YG
%A Gao S
%A Liu Y
%J Theranostics
%V 14
%N 8
%D 2024
%M 38855182
%F 11.6
%R 10.7150/thno.96027
%X Patient-derived organoids (PDOs) have emerged as a promising platform for clinical and translational studies. A strong correlation exists between clinical outcomes and the use of PDOs to predict the efficacy of chemotherapy and/or radiotherapy. To standardize interpretation and enhance scientific communication in the field of cancer precision medicine, we revisit the concept of PDO-based drug sensitivity testing (DST). We present an expert consensus-driven approach for medication selection aimed at predicting patient responses. To further standardize PDO-based DST, we propose guidelines for clarification and characterization. Additionally, we identify several major challenges in clinical prediction when utilizing PDOs.